ProCE Banner Activity

CME

Next-Generation Non-Hodgkin Lymphoma Care: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

Video

Listen to Julio C. Chavez, MD, MS, an academic-based medical oncologist, and Alan Skarbnik, MD, a community-based medical oncologist, discuss the emerging role of CELMoDs in NHL, including available data and ongoing clinical trials with these agents.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 21, 2024

Expiration: August 20, 2025

Share

Faculty

Julio C Chavez

Julio C Chavez, MD, MS

Associate Member
ICE-T Clinical Research Medical Director Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Alan Skarbnik

Alan Skarbnik, MD

Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for hematologists/oncologists and other allied healthcare professionals involved in the treatment of patients with NHL. 

Program Learning Goal

The goal of this program is to improve learners’ understanding of the latest data on investigational protein degradation pathway inhibitors for the treatment of NHL in preparation for clinical use of these agents. 

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Describe the rationale for therapeutically targeting dysregulation of the ubiquitin-proteasome system in patients with NHL

  • Evaluate safety and efficacy data of investigational agents that target protein degradation pathways in NHL treatment, specifically considering the potential clinical application of cereblon (CRBN) E3 ligase modulators (CELMoDs)

  • Identify eligible patients with NHL who are candidates for enrollment on ongoing clinical trials evaluating novel protein degraders

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Julio C Chavez, MD, MS

Associate Member
ICE-T Clinical Research Medical Director Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Julio C. Chavez, MD, MS: researcher: Genmab, Kite/Gilead, Merck; consultant/advisor/speaker: Allogene, AstraZeneca, Bristol Myers Squibb, Cellectar, Genmab, Kite/Gilead, Novartis; independent contractor: BeiGene, Lilly.

Alan Skarbnik, MD

Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Alan Skarbnik, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Genentech, Janssen, Jazz, Kite, Lilly, Pharmacyclics, SeaGen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 21, 2024, through August 20, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.